May 13, 2025: MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall Survival of 54%, demonstrating high efficacy and significant clinical improvement over currently [...] 